

IDARAM

R-IDARAM comprised of **Rituximab** 375 mg/m² (day 1), idarubicin 10 mg/m²(day 2 and 3); dexamethasone 100 mg/m² (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m² (1 h. infusion in day 2 and 3); methotrexate 2 g/m² (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of **Rituximab** 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.

Results indicate that R-IDARAM regimen with intrathecal immunochemotherapy is generally well tolerated and produces a high complete response rate and survival rate in **Primary central nervous system lymphoma**¹⁾.

¹⁾

Qian L, Zhou C, Shen J, Cen J, Yin W. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy. Oncotarget. 2016 Mar 25. doi: 10.18632/oncotarget.8370. [Epub ahead of print] PubMed PMID: 27029056.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**



Permanent link:

<https://neurosurgerywiki.com/wiki/doku.php?id=idaram>

Last update: **2025/04/29 20:20**